RBPJL and esophageal squamous cell carcinoma: This could be explained as follows: firstly, the data were obtained from the TCGA database, rather than PD1‐treated patients, and hence, the results did not reflect the impact of RBPJL expression on toripalimab sensitivity; secondly, RBPJL mutation might also be involved in secondary drug resistance, which requires further research in ESCC patients treated with PD‐1.